News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

Filter by:

All News Press Releases Events

10.07.2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Innoviva Specialty Therapeutics today announced that it will deliver data from six presentations at IDWeek 2025, including clinical data, and microbiologic surveillance data.

Read More

08.13.2025

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Read More

06.10.2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Read More

05.20.2025

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

ZEVTERA is now commercially available in the U.S. to treat methicillin-resistant Staphylococcus aureus (MRSA).

Read More

12.16.2024

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Read More

10.15.2024

Innoviva Specialty Therapeutics to Present New Clinical Data from its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Read More

09.19.2024

Innoviva Specialty Therapeutics Presents Findings from Subgroup Analyses of zoliflodacin in uncomplicated gonorrhea at the 2024 Sexually Transmitted Infections Conference

Read More

08.09.2024

Innoviva Specialty Therapeutics’ Pathogen-Targeted Antibiotic XACDURO® is Nominated for the 2024 Prix Galien USA Best Biotechnology Product Award

Read More

07.01.2024

Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

Read More

05.20.2024

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Read More